THE EFFECT OF PIRFENIDONE ON CHRYSOTILE ASBESTOS-INDUCED PULMONARY FIBROSIS IN THE HAMSTER (ANTI-INFLAMMATORY DRUG)

THE EFFECT OF PIRFENIDONE ON CHRYSOTILE ASBESTOS-INDUCED PULMONARY FIBROSIS IN THE HAMSTER (ANTI-INFLAMMATORY DRUG)

Bibliographic Details
Main Author:	Grimm, Scott Wayne, 1961-
Language:	en_US
Published:	The University of Arizona. 1986
Subjects:	Lungs > Diseases > Treatment. Lungs > Dust diseases. Pulmonary pharmacology.
Online Access:	http://hdl.handle.net/10150/276781

Similar Items

Role of pirfenidone in the management of pulmonary fibrosis
by: Meyer KC, et al.
Published: (2017-04-01)

Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis
by: Ulrich Costabel, et al.
Published: (2019-03-01)

South–West of England’s Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
by: Shaney L. Barratt, et al.
Published: (2018-12-01)

Lung Transplantation in Idiopathic Pulmonary Fibrosis
by: Rosalía Laporta Hernandez, et al.
Published: (2018-08-01)

Pulmonary Fibrosis
Published: (2019)

Quantitative Evaluation of Fibrosis in IPF Patients: Meaning of Diffuse Pulmonary Ossification
by: Monica Palermo, et al.
Published: (2021-01-01)

Histological findings and lung dust analysis as the basis for occupational disease compensation in asbestos-related lung cancer in Germany
by: Inke Sabine Feder, et al.
Published: (2018-01-01)

Assessing the Effectiveness of Pirfenidone in Idiopathic Pulmonary Fibrosis: Long-Term, Real-World Data from European IPF Registry (eurIPFreg)
by: Ekaterina Krauss, et al.
Published: (2020-11-01)

Composition and modification of the lung microbiome in patients with idiopathic pulmonary fibrosis
by: Victoria Maria Ruta, et al.
Published: (2020-10-01)

Pulmonary morphometric histopathology of saline or paraquat-exposed rats treated with the collagen inhibitor dehydroproline
by: Onyeama, Henry Patrick.
Published: (2015)

Occupational risk index of pneumoconiosis
by: Liu, Linjun, et al.
Published: (2015)

Authors’ response (April 30, 2018) to the letter to the editor concerning the paper “Histological findings and lung dust analysis as the basis for occupational disease compensation in asbestos-related lung cancer in Germany”
by: Inke Sabine Feder, et al.
Published: (2018-12-01)

Differential diagnosis of idiopathic pulmonary fibrosis
by: E. I. Shmelev, et al.
Published: (2020-03-01)

Authors’ response (March 14, 2018) to the letter to the Editor concerning the paper “Histological findings and lung dust analysis as the basis for occupational disease compensation in asbestos-related lung cancer in Germany”
by: Inke Sabine Feder, et al.
Published: (2018-12-01)

Idiopathic Pulmonary Fibrosis (IPF): An Overview
by: Shaney L. Barratt, et al.
Published: (2018-08-01)

Dyspnoea with progressive “idiopathic” pulmonary fibrosis
by: Chahat Puri, et al.
Published: (2021-07-01)

Erythropoietin: role in idiopathic pulmonary fibrosis revisited
by: Contributors A.O Abdel-Aziz, et al.
Published: (2020-01-01)

Patient considerations and drug selection in the treatment of idiopathic pulmonary fibrosis
by: Trawinska MA, et al.
Published: (2016-04-01)

Progression in the Management of Non-Idiopathic Pulmonary Fibrosis Interstitial Lung Diseases, Where Are We Now and Where We Would Like to Be
by: Tinne Goos, et al.
Published: (2021-03-01)

Mediastinal lymph node enlargement in idiopathic pulmonary fibrosis: relationships with disease progression and pulmonary function trends
by: Giacomo Sgalla, et al.
Published: (2020-09-01)

Clinical course and management of idiopathic pulmonary fibrosis
by: Caitlin Quinn, et al.
Published: (2019-12-01)

Differences between Acute Exacerbations of Idiopathic Pulmonary Fibrosis and Other Interstitial Lung Diseases
by: Paola Faverio, et al.
Published: (2021-09-01)

Inflammatory leukocyte phenotypes correlate with disease progression in idiopathic pulmonary fibrosis
by: Bethany B. Moore, et al.
Published: (2014-12-01)

Pharmacological Interactions of Nintedanib and Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis in Times of COVID-19 Pandemic
by: José M. Serra López-Matencio, et al.
Published: (2021-08-01)

Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the Australian IPF registry
by: Helen E. Jo, et al.
Published: (2018-01-01)

The importance of pulmonary rehabilitation in lung transplantation
by: Manivel Arumugam, et al.
Published: (2021-01-01)

Retrospective cohort study of patients qualified for lung transplantation due to idiopathic pulmonary fibrosis – single-centre experience
by: Marek Ochman, et al.
Published: (2019-01-01)

Mortality in Miners with Coal-Workers’ Pneumoconiosis in the Czech Republic in the Period 1992–2013
by: Hana Tomášková, et al.
Published: (2017-03-01)

CDK4/6 inhibition enhances pulmonary inflammatory infiltration in bleomycin-induced lung fibrosis
by: Anna Birnhuber, et al.
Published: (2020-07-01)

Practical application and validation of the 2018 ATS/ERS/JRS/ALAT and Fleischner Society guidelines for the diagnosis of idiopathic pulmonary fibrosis
by: Angela R. Shih, et al.
Published: (2021-04-01)

Measuring Surgery Outcomes of Lung Cancer Patients with Concomitant Pulmonary Fibrosis: A Review of the Literature
by: Taichiro Goto
Published: (2018-07-01)

Idiopathic pulmonary fibrosis: diagnostic pitfalls and therapeutic challenges
by: Spagnolo Paolo, et al.
Published: (2012-11-01)

Computed tomography in evaluating the development of different types of pulmonary fibrosis in patients with interstitial lung diseases
by: A. A. Speranskaya, et al.
Published: (2016-03-01)

Idiopathic pulmonary fibrosis: pathogenesis and management
by: Giacomo Sgalla, et al.
Published: (2018-02-01)

Spectrum of diffuse parenchymal lung diseases with special reference to idiopathic pulmonary fibrosis and connective tissue disease: An eastern India experience
by: Somenath Kundu, et al.
Published: (2014-01-01)

Effects of pulmonary rehabilitation on dyspnea and functional capacity on waiting list for lung transplantation: According to obstructive or restrictive pulmonary disease
by: Lutfiye Kilic, et al.
Published: (2020-01-01)

Global incidence and prevalence of idiopathic pulmonary fibrosis
by: Toby M. Maher, et al.
Published: (2021-07-01)

Idiopathic and immune‐related pulmonary fibrosis: diagnostic and therapeutic challenges
by: Andrew McLean‐Tooke, et al.
Published: (2019-01-01)

Relationship between ferromagnetic particles and airborne chrysotile fibres in the asbestos mines and mills of Quebec
by: Djamgouz, O. T.
Published: (1982)

Outcomes of Atrioseptostomy with Stenting in Patients with Pulmonary Arterial Hypertension from a Large Single-Institution Cohort
by: Sergey V. Gorbachevsky, et al.
Published: (2020-09-01)

Cannot write session to /tmp/vufind_sessions/sess_qvr5ckbjea97f46n48oab8r87f